View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 8, 2022

Annexon concludes enrolment in Phase II geographic atrophy treatment trial

The trial will assess the monthly and alternate-month dosing regimen of ANX007 in 270 patients.

Annexon has concluded subject enrolment in the Phase II ARCHER clinical trial of its anti-C1q candidate, ANX007, in individuals with geographic atrophy (GA).

An antigen-binding fragment (Fab), ANX007 is formulated for intravitreal administration. It is created for localised hindering of C1q and the classical complement pathway in neurodegenerative eye diseases. 

The multicentre, randomised, double-masked, placebo-controlled trial enrolled a total of 270 GA patients

It will assess monthly as well as alternate-month dosing regimen of ANX007. 

Trial subjects will be categorised based on lesion location, with nearly 50% of the enrolled patients having non-foveal lesions, a risk factor for quicker progression. 

Analysing the variation in the GA lesion area, as assessed by fundus autofluorescence (FAF) is the primary efficacy endpoint of the trial.

The company intends to report topline results on the primary endpoint in the first half of next year, following treatment for a year.

Furthermore, complete data is anticipated on concluding the off-treatment period of six months.

According to data from a Phase Ib trial, ANX007 demonstrated to be well-tolerated and showed full target engagement and C1q inhibition in the eye for a minimum of four weeks. 

Annexon president and CEO Douglas Love said: “Excess classical complement activity in the retina is a potential driver of GA, and by stopping the classical complement pathway at its start, we believe we may halt the detrimental immune response and nerve damage that occurs in the eye. 

“With nearly half of patients enrolled having non-foveal lesions, the ARCHER trial is designed to evaluate slowing of GA lesion growth in both patients who are at risk for faster progression and in the overall patient population.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU